Enzyme and PH responsive 5-flurouracil (5-FU) loaded hydrogels based on OLSALAZINE (cas 15722-48-2) derivatives for colon-specific drug delivery
-
Add time:09/03/2019 Source:sciencedirect.com
Colon-specific drug delivery systems are efficient for increasing the availability of drugs at colon region and are desirable for the treatment of local diseases such as ulcerative colitis and colonic cancer. We synthesized an acryloyl chloride modified OLSALAZINE (cas 15722-48-2) (olsalazine-AC) as an azo crosslinker which was copolymerized with hydroxyethyl methacrylate (HEMA) and methacrylic acid (MAA), and developed two types of azo hydrogels which contained single network hydrogel and interpenetrating network hydrogel as an enzyme responsive and pH responsive controlled release carrier for colon-specific drug delivery. The structure of the azo crosslinker was characterized by FT-IR and 1H NMR spectra and the azo hydrogels were analyzed by using ultraviolet spectrophotometer and scanning electron microscopy. The in vitro release of the 5-flurouracil (5-FU) loaded azo hydrogels was carried out in PBS (pH 7.4), PBS (pH 2.0) and rat colonic fluid (RCF). The drug release profile revealed that 5-FU loaded in azo hydrogels released faster in rat colonic fluid. The results showed that these azo hydrogels could be potential drug carrier for colon-targeted delivery.
We also recommend Trading Suppliers and Manufacturers of OLSALAZINE (cas 15722-48-2). Pls Click Website Link as below: cas 15722-48-2 suppliers
Prev:Experimental burning rates and combustion mechanisms of single beryllium particles
Next:Synthesis of novel (bio) degradable linear azo polymers conjugated with OLSALAZINE (cas 15722-48-2)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Determination of mesalazine, a low bioavailability OLSALAZINE (cas 15722-48-2) metabolite in human plasma by UHPLC–MS/MS: Application to a pharmacokinetic study09/24/2019
- An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “OLSALAZINE (cas 15722-48-2)”09/10/2019
- Two three-dimensional pillared metal–OLSALAZINE (cas 15722-48-2) complexes based on infinite rod-shaped secondary building units09/09/2019
- Degradation kinetics of metronidazole and OLSALAZINE (cas 15722-48-2) by bacteria in ascending colon and in feces of healthy adults09/08/2019
- Full paperOld drug, new indication: OLSALAZINE (cas 15722-48-2) sodium reduced serum uric acid levels in mice via inhibiting xanthine oxidoreductase activity09/07/2019
- Research paperEx vivo evaluation of degradation rates of metronidazole and OLSALAZINE (cas 15722-48-2) in distal ileum and in cecum: The impact of prandial state09/06/2019
- On the encapsulation of OLSALAZINE (cas 15722-48-2) by β-cyclodextrin: A DFT-based computational and spectroscopic investigations09/05/2019
- Synthesis of novel (bio) degradable linear azo polymers conjugated with OLSALAZINE (cas 15722-48-2)09/04/2019


